Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292911 · ClinicalTrials.gov registry record · Phase 1
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT05292911 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 64 participants.
The verdict
NCT05292911, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
Interventions
- OTHER Placebo
- DRUG ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292911
The ClinicalTrials.gov registry entry for NCT05292911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05292911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05292911 about?
NCT05292911 is a clinical study titled "Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)". This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
What is the current status of trial NCT05292911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2022-03-09. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT05292911?
The interventions under investigation include: Placebo (OTHER), ALT-801 (DRUG).
Who is sponsoring clinical trial NCT05292911?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.